At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients With Type 2 Diabetes, Who Are Either Receiving No Current Treatment or Currently Treated With Diet and Exercise, Sulfonylurea, Metformin or a Combination of Sulfonylurea and Metformin
In Brief
A Phase 2 clinical trial evaluating Alogliptin and Placebo for Diabetes Mellitus. Completed, enrolled 265 participants.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with type 2 diabetes.
Study Details
Timeline
Interventions
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.